Open Orphan’s (ORPH) Maurice Treacy Hosts Value the Markets Webinar

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that the Company’s Chief Commercial Officer, Maurice Treacy, will be hosting a webinar alongside Value the Markets on Wednesday 30^th October 2019 at 19:00 (UK time).

Maurice Treacy will take the opportunity to update existing and potential shareholders on Open Orphan and will provide an insight on the Company’s Genomic Health Data platform, Europe’s first rare disease, advocacy-led genomic database. Maurice will also discuss how and why it is now so important for pharmaceutical companies to have access to patient data when developing new drugs.

For those wishing to join, the webinar will be available through webcast or dial-in facilities via the details provided below:

Webcast URL Link:

https://vtm.clickmeeting.com/orph 

Dial-in details:

UK dial-in number: +44 (20) 7048 4146

Irish dial-in number: +353 (76) 680 3062

Participant PIN: 214883#

When prompted, please provide participant’s pin code followed by # key

Enquiries:

Open Orphan Plc Tel: +353 (0)1 6440007
Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services business. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.